Sunday 18 October 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.8%, free cash flow grew 43.2% and total debt rose 5.65%, each against the same quarter a year earlier.
1.69
0.02
+1.20%
Follow ABOS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.35 | 4.39 | 3.89 | 5.77 | |
Current Ratio |
2.47 | 4.55 | 4.07 | 6.02 | |
Net Debt/EBITDA |
2.40 | 4.62 | 3.42 | 3.59 | |
Debt/Assets |
27.21% | 23.23% | 25.37% | 21.55% | |
Debt/Equity |
0.55 | 0.35 | 0.44 | 0.33 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.55 | 1.16 | 0.76 | 1.15 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(29.76) | (19.78) | (23.18) | (24.82) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.25) | (0.38) | (0.32) | (0.50) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.38) | (0.32) | (0.50) | |
Cash per Share |
1.53 | 2.03 | 1.93 | 2.09 | |
Shareholders Equity per Share |
0.79 | 1.38 | 1.16 | 1.54 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.79 | 1.38 | 1.16 | 1.54 | |
Free Cash Flow |
(18.07) | (24.13) | (19.10) | (30.49) | |
Working Capital |
68.67 | 103.87 | 92.25 | 110.20 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
56.77 | 86.94 | 69.85 | 83.11 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
7.74 | 1.36 | 3.10 | 1.51 | |
Average Assets |
143.95 | 169.05 | 180.91 | 204.60 | |
Average Common Equity |
87.17 | 121.50 | 126.12 | 155.19 |
Columns are period end dates